FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109078648> ?p ?o ?g. }

• W2109078648 endingPage "547" @default.
• W2109078648 startingPage "541" @default.
• W2109078648 abstract "Purpose The Pediatric Oncology Group adopted a histology-based approach to non-Hodgkin's lymphoma and treated patients with advanced large-cell lymphoma on a separate protocol (doxorubicin, vincristine, prednisone, 6-mercaptopurin, and methotrexate; APO regimen). In this study, we assessed the effects of an intense antimetabolite therapy alternating with APO on overall survival (OS) and event-free survival (EFS) and looked into biologic correlates. Patients and Methods From December 1994 to April 2000, we enrolled 180 eligible pediatric patients with stage III/IV large-cell lymphoma (LCL); 90 patients were randomly assigned to the intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC) arm, 85 patients to the APO arm, and five patients directly to the APO arm by study design due to CNS involvement. Planned therapy duration was 12 months. Results The 4-year EFS for all patients was 67.4% (SE, 4.2%), and OS was 80.1% (SE, 3.6%) without any significant difference between the two arms. The 4-year EFS and OS were 71.8% (SE, 6.1%) and 88.1% (SE, 4.4%), respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) and 70.3% (SE, 9.0%), respectively, for patients with diffuse large B-cell lymphoma. Only 11 patients required radiation (due to unresponsive bulky disease or CNS involvement). The IDM/HiDAC arm was associated with more toxicity. Conclusion The efficacy of incorporating IDM/HiDAC in the treatment plan of pediatric and adolescent patients with advanced-stage LCL was inconclusive as to its effect on EFS, regardless of the lymphoma phenotype. It cannot be excluded that with a higher number of patients, one treatment could prove superior and future studies will build on these data." @default.
• W2109078648 created "2016-06-24" @default.
• W2109078648 creator A5009716898 @default.
• W2109078648 creator A5022226444 @default.
• W2109078648 creator A5023092047 @default.
• W2109078648 creator A5027364145 @default.
• W2109078648 creator A5030019570 @default.
• W2109078648 creator A5034640156 @default.
• W2109078648 creator A5037778719 @default.
• W2109078648 creator A5044283278 @default.
• W2109078648 creator A5048012532 @default.
• W2109078648 creator A5072375420 @default.
• W2109078648 creator A5087587424 @default.
• W2109078648 date "2005-01-20" @default.
• W2109078648 modified "2023-10-10" @default.
• W2109078648 title "Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating Intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial" @default.
• W2109078648 cites W1672417844 @default.
• W2109078648 cites W17155469 @default.
• W2109078648 cites W1785998771 @default.
• W2109078648 cites W1867200418 @default.
• W2109078648 cites W1939376872 @default.
• W2109078648 cites W1949104778 @default.
• W2109078648 cites W2034655348 @default.
• W2109078648 cites W2038252730 @default.
• W2109078648 cites W2041391879 @default.
• W2109078648 cites W2041652923 @default.
• W2109078648 cites W2043564629 @default.
• W2109078648 cites W2044934343 @default.
• W2109078648 cites W2049156458 @default.
• W2109078648 cites W2075794516 @default.
• W2109078648 cites W2079538092 @default.
• W2109078648 cites W2107202569 @default.
• W2109078648 cites W2125114406 @default.
• W2109078648 cites W2156073127 @default.
• W2109078648 cites W2177155371 @default.
• W2109078648 cites W2229769287 @default.
• W2109078648 cites W2317207760 @default.
• W2109078648 cites W2438804093 @default.
• W2109078648 cites W4252168887 @default.
• W2109078648 cites W4293241248 @default.
• W2109078648 doi "https://doi.org/10.1200/jco.2005.11.075" @default.
• W2109078648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15659500" @default.
• W2109078648 hasPublicationYear "2005" @default.
• W2109078648 type Work @default.
• W2109078648 sameAs 2109078648 @default.
• W2109078648 citedByCount "127" @default.
• W2109078648 countsByYear W21090786482012 @default.
• W2109078648 countsByYear W21090786482013 @default.
• W2109078648 countsByYear W21090786482014 @default.
• W2109078648 countsByYear W21090786482015 @default.
• W2109078648 countsByYear W21090786482016 @default.
• W2109078648 countsByYear W21090786482017 @default.
• W2109078648 countsByYear W21090786482018 @default.
• W2109078648 countsByYear W21090786482019 @default.
• W2109078648 countsByYear W21090786482020 @default.
• W2109078648 countsByYear W21090786482021 @default.
• W2109078648 countsByYear W21090786482022 @default.
• W2109078648 countsByYear W21090786482023 @default.
• W2109078648 crossrefType "journal-article" @default.
• W2109078648 hasAuthorship W2109078648A5009716898 @default.
• W2109078648 hasAuthorship W2109078648A5022226444 @default.
• W2109078648 hasAuthorship W2109078648A5023092047 @default.
• W2109078648 hasAuthorship W2109078648A5027364145 @default.
• W2109078648 hasAuthorship W2109078648A5030019570 @default.
• W2109078648 hasAuthorship W2109078648A5034640156 @default.
• W2109078648 hasAuthorship W2109078648A5037778719 @default.
• W2109078648 hasAuthorship W2109078648A5044283278 @default.
• W2109078648 hasAuthorship W2109078648A5048012532 @default.
• W2109078648 hasAuthorship W2109078648A5072375420 @default.
• W2109078648 hasAuthorship W2109078648A5087587424 @default.
• W2109078648 hasConcept C126322002 @default.
• W2109078648 hasConcept C141071460 @default.
• W2109078648 hasConcept C143998085 @default.
• W2109078648 hasConcept C2776694085 @default.
• W2109078648 hasConcept C2776755627 @default.
• W2109078648 hasConcept C2778041864 @default.
• W2109078648 hasConcept C2778397455 @default.
• W2109078648 hasConcept C2778720950 @default.
• W2109078648 hasConcept C2779338263 @default.
• W2109078648 hasConcept C2779429289 @default.
• W2109078648 hasConcept C2781059491 @default.
• W2109078648 hasConcept C2781413609 @default.
• W2109078648 hasConcept C71924100 @default.
• W2109078648 hasConcept C90924648 @default.
• W2109078648 hasConceptScore W2109078648C126322002 @default.
• W2109078648 hasConceptScore W2109078648C141071460 @default.
• W2109078648 hasConceptScore W2109078648C143998085 @default.
• W2109078648 hasConceptScore W2109078648C2776694085 @default.
• W2109078648 hasConceptScore W2109078648C2776755627 @default.
• W2109078648 hasConceptScore W2109078648C2778041864 @default.
• W2109078648 hasConceptScore W2109078648C2778397455 @default.
• W2109078648 hasConceptScore W2109078648C2778720950 @default.
• W2109078648 hasConceptScore W2109078648C2779338263 @default.
• W2109078648 hasConceptScore W2109078648C2779429289 @default.
• W2109078648 hasConceptScore W2109078648C2781059491 @default.
• W2109078648 hasConceptScore W2109078648C2781413609 @default.
• W2109078648 hasConceptScore W2109078648C71924100 @default.
• W2109078648 hasConceptScore W2109078648C90924648 @default.

• next